Hongri Pharmaceutical was launched on October 30, 2009. Tianjin Hongri Pharmaceutical Co., Ltd. was founded in September 1996. It is a high-quality and innovative private pharmaceutical company. Its products cover the three major fields of sepsis, cerebrovascular drugs, and blood system drugs.
Company profile of Hongri Pharmaceutical:
1. Tianjin Hongri Pharmaceutical Co., Ltd. was established in 1996 and is one of the first companies in the country to be listed on the GEM. So far, it has developed into a high-tech pharmaceutical and health industry cluster spanning finished drugs, traditional Chinese medicine industry clusters, pharmaceutical excipients and APIs, medical devices and many other fields, integrating investment and financing, production, research and development, and sales, with more than 60 subsidiaries. family, with more than 6,000 employees. In recent years, the company has successively won many honors such as National High-tech Enterprise and National Technological Innovation Demonstration Enterprise, and has been ranked among the top 100 in China's pharmaceutical industry. In 2019, the main business income was 5 billion yuan, total assets were 8.454 billion yuan, and tax payment was 690 million yuan.
2. Scientific and technological innovation and industrialization of results are the driving force for the continuous development of Hongri Pharmaceutical. Hongri Pharmaceutical relies on the two national technology platforms of the established National Enterprise Technology Center and the National and Local Joint Engineering Research Center for Key Technologies of Traditional Chinese Medicine Formula Granules, and cooperates with well-known academicians such as Zhong Nanshan and Zhang Boli to continue to carry out anti-tumor and Xuebijing treatments for COVID-19, Innovative research on key technologies for the secondary development of Chinese patent medicines.
3. Focusing on solving critical illness problems, pursuing the value of saving lives and reducing mortality, and taking the creation of a killer product group as the innovation direction, develop world-class stem cell treatment technology, sepsis Innovative drugs for critical illness and anti-tumor small molecule drugs. Currently, it has 5 Class 1 new drugs including KB and PD-L1, more than 40 projects under research, nearly 400 valid patents, and dozens of new products are about to be launched.
4. Hongri Pharmaceutical’s product with independent intellectual property rights, Xuebijing Injection, has filled a gap in the world’s sepsis treatment field. In 2019, a research paper was published in the top international journal "Critical Medicine". Xuebijing effectively reduced the fatality rate of severe pneumonia by 8.8, and was called "a model of Chinese medicine going abroad" by Academician Zhong Nanshan.